Medical devices, healthcare technology and the business of care
510(k) clearance · K260215

BD OneFlow LST; BD OneFlow B-CLPD T1; BD FACSLyric Flow Cytometer, 8-color [4-2-2], 10-color [4-3-3], 12-color (4-3-5)

Bd Biosciences · Decision date Oct 20, 2026

MEDTECHLEDGER EXPLANATIONK260215

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-20 for 510(k) K260215, received 01/23/2026, covering BD OneFlow LST, BD OneFlow B-CLPD T1 and the BD FACSLyric Flow Cytometer in 8-color [4-2-2], 10-color [4-3-3] and 12-color (4-3-5) configurations. The applicant is BD Biosciences, Milpitas, CA. The device classification is Flow Cytometric Test System For Hematopoietic Neoplasms under 21 CFR 864.7010, product code PWD with subsequent code OYE, in the Hematology specialty with an Immunology review panel. SESE means clearance, not PMA approval.

The review document excerpt describes BD OneFlow LST as an aid in identifying hematologically abnormal mature NK-cell lineages in patients having or suspected of having such findings, and notes in vitro diagnostic use with Kaluza C data analysis software. The excerpt is truncated and does not state the full intended use, the B-CLPD T1 indication, or the basis for the equivalence determination. No summary or decision summary content was available in the retrieved material, so clinical performance data and any labeling limitations remain unknown.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Hematology
Decision date
Oct 20, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260215
Regulatory pathway
510(k) premarket notification
Product code
PWD
Decision code
SESE
Decision date
Oct 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Flow Cytometric Test System For Hematopoietic Neoplasms.

Product code
PWD
FDA device class
2

FDA decision timeline

  1. K260215 received

    Application receipt date recorded by FDA.

  2. K260215 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bd Biosciences

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Milpitas, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records